Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory

OncoImmunology

Volumn 4, Issue 4, 2015, Pages

  Wu, Junjie ^a   Waxman, David J ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; Chemoimmunotherapy; Chemotherapy; Cyclophosphamide; Drug scheduling; GL261 glioma; Glioblastoma; Immune memory; Metronomic chemotherapy; NK cells

Indexed keywords

CYCLOPHOSPHAMIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GLIOMA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REGULATORY T LYMPHOCYTE; TUMOR ABLATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

EID: 84929632877     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1005521     Document Type: Article

References (76)

1. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488:522-6; PMID:22854781; http://dx. doi. org/ 10. 1038/nature11287
2. Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 2014; 514:54-8; PMID:25079331; http://dx. doi. org/10. 1038/nature13556
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501:338-45; PMID:24048066; http://dx. doi. org/10. 1038/ nature12625
4. Barkholt L, Bregni M. Current immunotherapy for solid tumors. Immunotherapy 2009; 1:483-93; PMID:20635964; http://dx. doi. org/10. 2217/ imt. 09. 13
5. Beatty PL, Cascio S, Lutz E. Tumor immunology: basic and clinical advances. Cancer Res 2011; 71:4338-43; PMID:21712409; http://dx. doi. org/10. 1158/0008-5472. CAN-11-0717
6. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011; 23:286-92; PMID: 21185705; http://dx. doi. org/10. 1016/j. coi. 2010. 11. 013
7. Kandalaft LE, Singh N, Liao JB, Facciabene A, Berek JS, Powell DJ, Jr., Coukos G. The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 2010; 116:222-33; PMID:19959212; http://dx. doi. org/10. 1016/j. ygyno. 2009. 11. 001
8. Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res 2007; 13:4016-25; PMID:17606736; http://dx. doi. org/10. 1158/1078-0432. CCR-07-0016
9. Ferris RL, Jaffee EM, Ferrone S. Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28:4390-9; PMID:20697078; http://dx. doi. org/10. 1200/ JCO. 2009. 27. 6360
10. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37:499-507; PMID:21074065; http://dx. doi. org/10. 1053/j. seminoncol. 2010. 09. 007
11. Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther 2013; 21:348-57; PMID:23011032; http://dx. doi. org/10. 1038/ mt. 2012. 204
12. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 2011; 17:6958-62; PMID:21900389; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1595
13. Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx. doi. org/10. 4161/onci. 27878
14. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx. doi. org/10. 1038/onc. 2009. 356
15. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30:1147-58; PMID:21151176; http://dx. doi. org/ 10. 1038/onc. 2010. 500
16. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx. doi. org/10. 1084/ jem. 20050915
17. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx. doi. org/ 10. 1038/nm1523
18. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 2013; 62:203-16; PMID:23389507; http://dx. doi. org/10. 1007/s00262-012-1388-0
19. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx. doi. org/10. 1172/JCI35180
20. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6:638-47; PMID:19786984; http://dx. doi. org/ 10. 1038/nrclinonc. 2009. 146
21. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http:// dx. doi. org/10. 1158/0008-5472. CAN-10-2788
22. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, Baccarini S, Maccari S, Ramoni C, Belardelli F, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13:644-53; PMID:17255288; http://dx. doi. org/10. 1158/1078-0432. CCR-06-1209
23. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, Proietti E. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870
24. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33:369-83; PMID:21611872; http://dx. doi. org/10. 1007/s00281-011-0245-0
25. Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, et al. Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res 2009; 69:4309-18; PMID:19435909; http://dx. doi. org/10. 1158/0008-5472. CAN-08-4102
26. Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012; 72:1103-15; PMID:22237627; http://dx. doi. org/10. 1158/0008-5472. CAN-11-3380
27. Chang CL, Hsu YT, Wu CC, Lai YZ, Wang C, Yang YC, Wu TC, Hung CF. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res 2013; 73:119-27; PMID:23108141; http://dx. doi. org/10. 1158/0008-5472. CAN-12-2225
28. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 2014; 11:413-31; PMID:24913374; http://dx. doi. org/ 10. 1038/nrclinonc. 2014. 89
29. Chen CS, Doloff JC, Waxman DJ. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia 2014; 16:84-96; PMID:24563621
30. Wu J, Waxman DJ. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett 2014; 353:272-80; PMID:25069038; http://dx. doi. org/10. 1016/j. canlet. 2014. 07. 033
31. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31-7; PMID:8164737; http://dx. doi. org/10. 1038/369031a0
32. Pardo J, Balkow S, Anel A, Simon MM. Granzymes are essential for natural killer cell-mediated and perf-facilitated tumor control. Eur J Immunol 2002; 32:2881-7; PMID:12355441; http://dx. doi. org/10. 1002/ 1521-4141(2002010)32:10%3c2881::AIDIMMU2881% 3e3. 0. CO;2-K
33. Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 1994; 76:977-87; PMID:8137431; http://dx. doi. org/10. 1016/0092-8674(94)90376-X
34. Peterson RA. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 2012; 40:186-204; PMID:22222887; http://dx. doi. org/10. 1177/0192623311430693
35. Gautron AS, Dominguez-Villar M, de Marcken M, Hafler DA. Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells. Eur J Immunol 2014; 44:2703-11; PMID:24838857; http://dx. doi. org/ 10. 1002/eji. 201344392
36. Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol 2006; 126:32-41; PMID:16417215; http://dx. doi. org/10. 1038/sj. jid. 5700001
37. Shevach EM. Mechanisms of foxp3+ T regulatory cellmediated suppression. Immunity 2009; 30:636-45; PMID:19464986; http://dx. doi. org/10. 1016/j. immuni. 2009. 04. 010
38. Soudja SM, Ruiz AL, Marie JC, Lauvau G. Inflammatory monocytes activate memory CD8(+) T and innate NK lymphocytes independent of cognate antigen during microbial pathogen invasion. Immunity 2012; 37:549-62; PMID:22940097; http://dx. doi. org/ 10. 1016/j. immuni. 2012. 05. 029
39. Mouchemore KA, Pixley FJ. CSF-1 signaling in macrophages: pleiotrophy through phosphotyrosine-based signaling pathways. Crit Rev Clin Lab Sci 2012; 49:49-61; PMID:22468857; http://dx. doi. org/10. 3109/ 10408363. 2012. 666845
40. Noronha V, Krishna MV, Patil V, Joshi A, Banavali SD, Prabhash K. Metronomic therapy: chemotherapy revisited. Indian J Cancer 2013; 50:142-8; PMID:23979206; http://dx. doi. org/10. 4103/0019-509X. 117027
41. Emens LA. Chemoimmunotherapy. Cancer J 2010; 16:295-303; PMID:20693839; http://dx. doi. org/ 10. 1097/PPO. 0b013e3181eb5066
42. Bouche G, Andre N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, et al. Lessons from the fourth metronomic and anti-angiogenic therapy meeting, 24-25 june 2014, milan. Ecancermedicalscience 2014; 8:463; PMID:25228919
43. Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL, Nikolich-Zugich J. Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol 2014; 193:757-63; PMID:24913978; http://dx. doi. org/ 10. 4049/jimmunol. 1400188
44. Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, Kruse C, Jadus M, Chen TC, Schijns VE. Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology 2012; 1:298-305; PMID:22737605; http://dx. doi. org/ 10. 4161/onci. 19068
45. Doloff JC, Chen CS, Waxman DJ. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Mol Cancer 2014; 13:158; PMID:24965046; http://dx. doi. org/10. 1186/1476-4598-13-158
46. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; PMID:22926062; http://dx. doi. org/10. 1007/s00262-012-1343-0
47. Peng S, Lyford-Pike S, Akpeng B, Wu A, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 2013; 62:171-82; PMID:23011589; http://dx. doi. org/10. 1007/ s00262-012-1322-5
48. Mocikat R, Braumuller H, Gumy A, Egeter O, Ziegler H, Reusch U, Bubeck A, Louis J, Mailhammer R, Riethmüller G, et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003; 19:561-9; PMID:14563320; http://dx. doi. org/ 10. 1016/S1074-7613(03)00264-4
49. Salem ML, Hossain MS. In vivo acute depletion of CD8(+) T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. Int J Immunopharmacol 2000; 22:707-18; PMID:10884591; http://dx. doi. org/10. 1016/S0192-0561(00)00033-3
50. Alvarez M, Bouchlaka MN, Sckisel GD, Sungur CM, Chen M, Murphy WJ. Increased antitumor effects using IL-2 with anti-TGF-beta reveals competition between mouse NK and CD8 T cells. J Immunol 2014; 193:1709-16; PMID:25000978; http://dx. doi. org/10. 4049/jimmunol. 1400034
51. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002; 13:169-83; PMID:11900992; http://dx. doi. org/10. 1016/S1359-6101(01)00021-1
52. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014; 41:49-61; PMID:25035953; http://dx. doi. org/10. 1016/j. immuni. 2014. 06. 010
53. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20:87-103; PMID:21133840; http://dx. doi. org/10. 1615/CritRevEukarGeneExpr. v20. i2. 10
54. Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012:890178; PMID:22400040; http://dx. doi. org/ 10. 1155/2012/890178
55. Sevko A, Sade-Feldman M, Kanterman J, Michels T, Falk CS, Umansky L, Ramacher M, Kato M, Schadendorf D, Baniyash M, et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J Invest Dermatol 2013; 133:1610-9; PMID:23223128; http://dx. doi. org/ 10. 1038/jid. 2012. 444
56. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx. doi. org/10. 1038/nri2506
57. Moschella F, Valentini M, Arico E, Macchia I, Sestili P, D'Urso MT, Alessandri C, Belardelli F, Proietti E. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 2011; 71:3528-39; PMID:21444678; http://dx. doi. org/10. 1158/0008-5472. CAN-10-4523
58. Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx. doi. org/ 10. 1158/0008-5472. CAN-12-2027
59. Berard M, Brandt K, Bulfone-Paus S, Tough DF. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J Immunol 2003; 170:5018-26; PMID:12734346; http://dx. doi. org/10. 4049/ jimmunol. 170. 10. 5018
60. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immunebased mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21:15-25; PMID:23787994; http://dx. doi. org/ 10. 1038/cdd. 2013. 67
61. Rozados VR, Mainetti LE, Rico MJ, Zacarias Fluck MF, Matar P, Scharovsky OG. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 2010; 18:601-5; PMID:20939436; http://dx. doi. org/10. 3727/ 096504010X12777678141662
62. Denies S, Cicchelero L, Van Audenhove I, Sanders NN. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J Control Release 2014; 187:175-82; PMID:24887014; http://dx. doi. org/10. 1016/j. jconrel. 2014. 05. 045
63. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62:2731-5; PMID:12019144
64. Khan N, Hou H, Hodge S, Kuppusamy M, Chen EY, Eastman A, Kuppusamy P, Swartz HM. Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors. Adv Exp Med Biol 2014; 812:105-11; PMID:24729221; http://dx. doi. org/10. 1007/978-1-4939-0620-8_14
65. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-24; PMID:10772661; http://dx. doi. org/10. 1172/JCI8829
66. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175
67. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005; 5:397-405; PMID:15864281; http://dx. doi. org/ 10. 1038/nrc1613
68. Nguyen A, Ho L, Wan Y. Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer. Front Oncol 2014; 4:145; PMID:24967214
69. Jia L, Waxman DJ. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 2013; 330:241-9; PMID:23228633; http://dx. doi. org/10. 1016/j. canlet. 2012. 11. 055
70. Adair JE, Johnston SK, Mrugala MM, Beard BC, Guyman LA, Baldock AL, Bridge CA, Hawkins-Daarud A, Gori JL, Born DE, et al. Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest 2014; 124:4082-92; PMID:25105369; http://dx. doi. org/10. 1172/ JCI76739
71. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx. doi. org/10. 1016/S1470-2045(09)70025-7
72. Wolff JE, Finlay JL. High-dose chemotherapy in childhood brain tumors. Onkologie 2004; 27:239-45; PMID:15249712; http://dx. doi. org/10. 1159/ 000077973
73. Abrahamsen TG, Lange BJ, Packer RJ, Venzon DJ, Allen JC, Craig CE, Patronas NJ, Katz DA, Goldwein JW, DeLaney TF, et al. A phase I and II trial of doseintensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors. J Pediatr Hematol Oncol 1995; 17:134-9; PMID:7749762; http://dx. doi. org/ 10. 1097/00043426-199505000-00006
74. Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP. High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study. J Clin Oncol 1997; 15:3258-65; PMID:9336363
75. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58:1627-34; PMID:19221744; http://dx. doi. org/10. 1007/s00262-009-0671-1
76. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 2013; 36:477-89; PMID:24145359; http://dx. doi. org/10. 1097/01. cji. 0000436722. 46675. 4a